ONL Therapeutics Completes Enrollment in Phase 2 GALAXY Trial
ONL Therapeutics completed enrollment in its global Phase 2 trial of xelafaslatide in patients with geographic atrophy associated with dry age-related macular degeneration.
ONL Therapeutics completed enrollment in its global Phase 2 trial of xelafaslatide in patients with geographic atrophy associated with dry age-related macular degeneration.